ORDOXTI
Live / Applied — Fifth extension granted (statement of use) (as of 07 Feb 2026)
What this means for you
Not registered yet, but its 09 May 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97400931
- Mark type
- Stylized text
- Filed
- 09 May 2022
- Published for opposition
- 24 Jan 2023
- Attorney of record
- Terrence J. McAllister
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral diseases and disorders, and for the treatment of pain
Owner
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, US
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, US
Prosecution history
- 07 Feb 2026 — SOU EXTENSION 5 GRANTED
- 13 Sept 2025 — SOU EXTENSION 5 FILED
- 30 Jan 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 13 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 30 Jun 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 30 Jun 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 30 Jun 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 28 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Feb 2025 — SOU EXTENSION 4 GRANTED
- 27 Feb 2025 — SOU EXTENSION 4 FILED
- 27 Feb 2025 — SOU TEAS EXTENSION RECEIVED
- 28 Aug 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 28 Aug 2024 — SOU EXTENSION 3 GRANTED
- 28 Aug 2024 — SOU EXTENSION 3 FILED
- 28 Aug 2024 — SOU TEAS EXTENSION RECEIVED